Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. QDEL
stocks logo

QDEL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
700.23M
-1.07%
0.424
-32.63%
712.38M
+2.83%
0.823
+11.22%
628.47M
+2.37%
0.179
+49.56%
Estimates Revision
The market is revising Downward the revenue expectations for QuidelOrtho Corporation (QDEL) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by -3.00%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-10.46%
In Past 3 Month
Stock Price
Go Down
down Image
-3.00%
In Past 3 Month
Wall Street analysts forecast QDEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QDEL is 34.60 USD with a low forecast of 22.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast QDEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QDEL is 34.60 USD with a low forecast of 22.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
3 Hold
1 Sell
Moderate Buy
Current: 27.820
sliders
Low
22.00
Averages
34.60
High
62.00
Current: 27.820
sliders
Low
22.00
Averages
34.60
High
62.00
Citi
Neutral
downgrade
$33 -> $23
2025-11-10
Reason
Citi
Price Target
$33 -> $23
2025-11-10
downgrade
Neutral
Reason
Citi lowered the firm's price target on QuidelOrtho to $23 from $33 and keeps a Neutral rating on the shares.
JPMorgan
Underweight
downgrade
$26 -> $22
2025-11-07
Reason
JPMorgan
Price Target
$26 -> $22
2025-11-07
downgrade
Underweight
Reason
JPMorgan lowered the firm's price target on QuidelOrtho to $22 from $26 and keeps an Underweight rating on the shares. The firm views the company's Q3 report as "noisy."
UBS
Neutral
maintain
$26 -> $31
2025-11-06
Reason
UBS
Price Target
$26 -> $31
2025-11-06
maintain
Neutral
Reason
UBS raised the firm's price target on QuidelOrtho to $31 from $26 and keeps a Neutral rating on the shares. QuidelOrtho posted a quarterly beat vs. expectations as its margin expansion is on track, the analyst tells investors in a research note.
Citi
Buy
downgrade
$50 -> $40
2025-08-06
Reason
Citi
Price Target
$50 -> $40
2025-08-06
downgrade
Buy
Reason
Citi lowered the firm's price target on QuidelOrtho to $40 from $50 and keeps a Buy rating on the shares. The firm views the company's Q2 report and cost actions planned for the back of half of 2025 positively.
Raymond James
Outperform
maintain
$60 -> $55
2025-08-06
Reason
Raymond James
Price Target
$60 -> $55
2025-08-06
maintain
Outperform
Reason
Raymond James lowered the firm's price target on QuidelOrtho to $55 from $60 and keeps an Outperform rating on the shares. QuidelOrtho reported a strong and "fairly clean" quarter, with revenues roughly in line with estimates, outperformance in Labs, and relatively in-line respiratory revenues, the analyst tells investors in a research note. Raymond James views the updated guidance as prudent given the "show me" nature of the story.
Nephron Research
Buy -> Hold
downgrade
$40
2025-07-09
Reason
Nephron Research
Price Target
$40
2025-07-09
downgrade
Buy -> Hold
Reason
Nephron Research downgraded QuidelOrtho to Hold from Buy with a $40 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for QuidelOrtho Corp (QDEL.O) is 13.10, compared to its 5-year average forward P/E of 15.91. For a more detailed relative valuation and DCF analysis to assess QuidelOrtho Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
15.91
Current PE
13.10
Overvalued PE
21.96
Undervalued PE
9.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
8.37
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
10.85
Undervalued EV/EBITDA
5.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.21
Current PS
0.00
Overvalued PS
3.92
Undervalued PS
0.50
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

QDEL News & Events

Events Timeline

(ET)
2025-11-05
17:20:05
QuidelOrtho projects FY25 adjusted EBITDA between $585M and $605M.
select
2025-11-05
17:07:20
QuidelOrtho Projects $70M-$100M in COVID-19 Revenue for FY25
select
2025-11-05
17:06:24
QuidelOrtho aims for adjusted EBITDA margins in the mid-to-high 20% range.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-25NASDAQ.COM
Insider Buying Update for Monday, November 24: QDEL, MTCH

  • QuidelOrtho Insider Purchase: CEO Brian J. Blaser bought 23,500 shares of QDEL for $501,577, with a current gain of about 21.0% as the stock trades at $25.83, up 6.1% on the day.

  • Match Group Insider Purchase: CEO Spencer M. Rascoff purchased 14,000 shares of MTCH for $445,691, marking his fourth buy in the past year, with a current gain of about 3.2% as the stock trades at $32.85, up 1.8% on the day.

[object Object]
Preview
1.0
11-24PRnewswire
QuidelOrtho To Participate In Upcoming Investor Conferences

  • Upcoming Investor Conferences: QuidelOrtho Corporation will participate in the Evercore ISI 8th Annual Healthcare Conference on December 2, 2025, and the Citi Global Healthcare Conference on December 3, 2025, with management team fireside chats scheduled for both events.

  • Access to Webcasts: Interested parties can access live webcasts and replays of the conferences through the "Events & Presentations" section on QuidelOrtho's Investor Relations website.

  • Company Overview: QuidelOrtho is a leading global provider of diagnostic solutions, specializing in various testing methods to improve patient outcomes and healthcare decisions.

  • Contact Information: For investor inquiries, Juliet Cunningham is the Vice President of Investor Relations, and for media inquiries, D. Nikki Wheeler is the Senior Director of Corporate Communications.

[object Object]
Preview
2.0
11-22CNBC
Midday Stock Highlights: Notable Movements from Oracle, Bath & Body Works, Gap, and Others

  • Oracle and Bath & Body Works Declines: Oracle's stock fell 4% amid concerns over AI valuations, while Bath & Body Works dropped 5% following downgrades from major analysts after disappointing third-quarter results.

  • Positive Movements for QuidelOrtho and Azenta: QuidelOrtho's shares rose 11% after CEO stock purchases, and Azenta's stock increased over 10% after reporting better-than-expected fiscal fourth-quarter earnings.

  • Enviri's Major Rally: Enviri's stock surged nearly 29% after announcing the sale of its waste division to Veolia for $3.04 billion and plans to spin off its other divisions.

  • Mixed Results for Other Companies: Elastic's stock tumbled 14% due to slowing cloud growth despite beating earnings expectations, while Gap and Ross Stores saw gains after exceeding sales forecasts.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is QuidelOrtho Corp (QDEL) stock price today?

The current price of QDEL is 27.82 USD — it has increased 1.05 % in the last trading day.

arrow icon

What is QuidelOrtho Corp (QDEL)'s business?

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.

arrow icon

What is the price predicton of QDEL Stock?

Wall Street analysts forecast QDEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QDEL is 34.60 USD with a low forecast of 22.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is QuidelOrtho Corp (QDEL)'s revenue for the last quarter?

QuidelOrtho Corp revenue for the last quarter amounts to 699.90M USD, decreased -3.74 % YoY.

arrow icon

What is QuidelOrtho Corp (QDEL)'s earnings per share (EPS) for the last quarter?

QuidelOrtho Corp. EPS for the last quarter amounts to -10.78 USD, increased 3493.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for QuidelOrtho Corp (QDEL)'s fundamentals?

The market is revising Downward the revenue expectations for QuidelOrtho Corporation (QDEL) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by -3.00%.
arrow icon

How many employees does QuidelOrtho Corp (QDEL). have?

QuidelOrtho Corp (QDEL) has 6600 emplpoyees as of December 05 2025.

arrow icon

What is QuidelOrtho Corp (QDEL) market cap?

Today QDEL has the market capitalization of 1.89B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free